The effects of sodium-glucose cotransporter 2 inhibitors beyond the cardio-renal-metabolic spectrum: Will gliflozins have a different fate than statins?
Theocharis KoufakisVasilis TsimihodimosSymeon MetallidisKalliopi KotsaMichael DoumasPublished in: Expert opinion on pharmacotherapy (2023)
Keyphrases